Clinical Trial

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2026-04-27
Trial Details
NCT Number NCT07099547
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Biliary Tract Carcinoma
Enrollment 60 participants
Start Date 2025-12-02
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01